戴納基 DYN 深滬

等待開盤 07-18 09:30:00 美东时间

9.40

+0.070

+0.75%

華盛通

立即下載

最高9.83
今開9.488
成交量 244.03万股
最低 9.30
昨收 9.33
總市值 10.72亿
52周最高 47.45
市盈率 ^靜 --
換手率 0.00%
52周最低 6.36
委比 22.42%
總股本 1.14亿
歷史最高 47.45
量比 0.69
振幅 5.68%
歷史最低 4.30
每手 1
風險率 12.20%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

中国中化携创新成果亮相第三届中国国际供应链促进博览会

（来源：中国化工信息周刊）关键词|中国中化亮相链博会共2183字 | 建议阅读时间5分钟 7月16日，以“链接...

07-16 23:18
Dyne shares up after CEO buys stock

Dyne Therapeutics (NASDAQ:DYN) shares rose on Wednesday after the company's CEO, John Cox, bought 100,000 shares of the company. The stock is up 6%. The CEO bought 100,000 shares between a price range...

07-16 22:46
Satellos Bioscience names new chief medical officer

Satellos Bioscience (TSX:MSCL:CA) appointed Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell joins Satellos from Dyne Therapeutics (DYN), where he most recently served as CMO and med...

07-16 19:34
JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $9

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Neutral and lowers the price target from $10 to $9.

07-16 00:19
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics announced the closing of its underwritten public offering, raising approximately $230 million by issuing 27,878,788 shares of common stock at $8.25 per share. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers. The company aims to develop therapeutics for genetically driven neuromuscular diseases, focusing on myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumera...

07-02 20:01
Dyne Therapeutics Secures $275M Loan Agreement

Dyne Therapeutics ( ($DYN) ) just unveiled an update. On June 27, 2025, Dyne Th...

07-01 04:44
Dyne Therapeutics shares are trading lower after the company announced a proposed $200 million common stock offering.

Dyne Therapeutics shares are trading lower after the company announced a propos...

07-01 04:12
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Dyne Therapeutics Inc. announced the commencement of an underwritten public offering of $200 million of its common stock, with an additional $30 million option for underwriters. The offering is being led by Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities. The final terms will be disclosed in a prospectus supplement filed with the SEC. The company focuses on developing therapies for genetically driven neuromuscular diseases such as my...

06-30 20:05
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

<p>Dyne Therapeutics secures a $275 million senior secured term loan facility with Hercules Capital to advance its DM1 and DMD programs, with $100 million upfront and additional funding tied to milestones. The financing supports clinical and regulatory progress, including potential U.S. Accelerated Approval submissions in 2026 and a first launch in DMD in 2027. Hercules Capital highlights its confidence in Dyne’s leadership and pipeline to addres...

06-30 20:01
美股周涨跌榜 | 获重大政策利好！Circle周涨80%；肿瘤AI诊断平台CAI周涨29.8%

获重大政策利好！Circle周涨80%，上市以来累涨超675%；TMC周涨51%，获韩国锌业战略投资；肿瘤AI诊断平台CAI本周登陆纳斯达克，周涨29.8%>>

06-21 10:28

派息除權日	每股總股息	派息日期
2002-05-30	0.08	2002-06-17
2002-02-27	0.08	2002-03-15
2001-11-29	0.08	2001-12-17
2001-08-29	0.08	2001-09-17
2001-05-29	0.08	2001-06-15
2001-02-27	0.08	2001-03-15
2000-11-29	0.08	2000-12-15
2000-08-29	0.08	2000-09-15
2000-05-26	0.15	2000-06-15
2000-02-24	0.04	2000-03-31
1999-12-01	0.01	1999-12-21
1999-09-01	0.01	1999-09-21
1999-06-01	0.01	1999-06-28
1999-03-04	0.01	1999-03-26
1998-12-01	0.01	1998-12-21
1998-09-01	0.01	1998-09-21
1998-05-28	0.01	1998-06-22
1998-03-09	0.01	1998-03-27
1997-12-01	0.01	1997-12-19
1997-08-22	0.01	1997-09-16
1997-05-21	0.01	1997-06-16
1997-02-13	0.01	1997-03-05
1996-11-27	0.01	1996-12-16
1996-07-25	0.01	1996-09-03
1996-05-16	0.01	1996-06-04
1996-03-21	0.01	1996-04-09
1995-12-14	0.01	1996-01-02
1995-09-21	0.01	1995-10-10
1995-06-16	0.01	1995-07-05
1995-03-01	0.01	1995-03-21
1994-12-01	0.01	1994-12-21
1994-08-31	0.01	1994-09-21
1994-06-01	0.01	1994-06-21
1994-03-01	0.01	1994-03-21
1984-10-03	0.66	1984-11-01
1984-07-03	0.66	1984-08-01
1984-04-04	0.66	1984-05-01
1984-01-04	0.66	1984-02-01
1983-10-03	0.62	1983-11-01
1983-07-05	0.62	1983-08-01
1983-04-05	0.62	1983-05-02
1983-01-04	0.62	1983-02-01
1982-10-04	0.62	1982-11-01
1982-07-02	0.62	1982-08-02
1982-04-02	0.62	1982-05-01
1982-01-05	0.62	1982-02-01
1981-10-05	0.60	1981-11-02
1981-07-06	0.60	1981-08-01
1981-04-06	0.60	1981-05-01
1981-01-05	0.60	1981-02-02
1980-10-06	0.60	1980-11-01
1980-07-03	0.60	1980-08-01
1980-04-02	0.57	1980-05-01
1980-01-03	0.57	1980-01-31
1979-10-02	0.57	1979-10-31
1979-07-02	0.57	1979-07-31
1979-04-03	0.57	1979-04-30
1979-01-03	0.57	1979-01-31
1978-10-02	0.57	1978-10-31
1978-07-02	0.57	1978-07-31
1978-04-03	0.57	1978-04-30
1978-01-03	0.57	1978-01-31
1977-10-02	0.55	1977-10-31
1977-06-30	0.55	1977-07-31
1977-04-03	0.55	1977-05-01

公司名稱	戴纳基
行業分類	电力
業務描述	Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

戴納基 DYN 深 滬

9.40

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

戴納基 DYN 深滬